PFIZER INC Q1 FY2025 earnings call

R&D Focus - Strengthening R&D organization to advance pipeline and productivity, intensifying commercial assessment and portfolio prioritization, with disciplined management of portfolio. Focus on cardiometabolic pipeline including obesity, with internal programs and potential external opportunities. Reshaping R&D organization under Chris Boshoff's leadership, with new leaders in oncology, vaccines, etc. - ### Commercial Excellence - Separated US and international operations, with refined commercial model. US team showed focus, strength in key products, and continuous improvement. International operations saw growth across all parts, with strong performance in products like Wintercare family, Nortech, Tatserv, and Blurbbrand. Oncology portfolio strong, with Tatsit and Brenna showing growth. Ionoid category also had growth, with Sibingo increasing in adoption. - ### Cost Management - Total adjusted operating expenses decreased 12% operationally. Adjusted SIA expenses decreased due to productivity improvements. Adjusted R&D expenses decreased due to pipeline optimization. Focus on cost improvement programs, with expectation of $7.7 billion in savings by end of 2027 to drive operational efficiency. - ### Capital Allocation - Strategy includes maintaining and growing dividend, reinvesting in business, and making value-enhancing share repurchases. Monetized Halyon shares to improve cash position and delever balance sheet.

In the first quarter of 2025, Pfizer Inc. recorded revenues of $13.7 billion, a 6% operational decline. The decline was due to lower PAX load and the impact of the IRA Medicare Part D redesign in the US. However, there was growth in several in-line products in the US and internationally. Key product segments contributing included the Windekl family, Commerdy, Hatseb, Neurotech, and LoBrena, while pack Lobid, Eliquis, Xeljanz, and Ibrance saw declines. Internationally, there was growth across various parts of the division, with the Vintechl family having robust growth though facing competition, and Northrop America seeing 40% revenue growth in the quarter.

Pfizer Inc. reaffirmed 2025 guidance: total company full-year 2025 revenues expected to be in the range of $61 to $64 billion, and full-year 2025 adjusted diluted earnings per share expected to be in the range of $2.80 to $3.00 a share. The company is trending towards the upper end of the adjusted diluted earnings per share guidance range, excluding potential impact from future trade changes.

Tariffs - Uncertainty around sector-specific tariffs, with potential impact on cash flows and bottom line. The 232 investigation on pharmaceuticals and national security concerns, with potential implications for manufacturing and supply chains. ### Macroeconomic Uncertainties - Volatile external environment, including trade and tariff policies, which could impact the business in both short and long term. Uncertainty around the timing and shape of COVID waves affecting Pexlovid sales.

Q: Vamil Divan asked about the commitment to maintaining and growing the dividend despite tariff uncertainty and views on the COVID business.

A: Dave Denton emphasized the dividend is a critical component of capital allocation strategy, focused on improving operating margin performance. Aamir Malik discussed Pexlovid utilization trends related to infection rates.

Q: Evan Seigerman asked about key aspects of the profile for a potential obesity asset.

A: Chris Boshoff mentioned focus on cardiovascular metabolic strategies, internal oral medicines including a GI antagonist in phase two, and personalized combinations. Andrew Baum underlined clinical and commercial differentiation.

Q: Tim Anderson asked about tariffs, including 232 investigation and MFN legislation.

A: Albert Bourla discussed 232 investigation focus on national security, engagement with administration, and cautious optimism. Steve Scala's questions on MFN and US plant utilization were addressed, with Albert Bourla and Dave Denton commenting on administration priorities and plant utilization.

Q: Umer Raffat asked about dividend, OpEx cuts, tariff impact, and distinction between friendly and unfriendly countries.

A: Dave Denton spoke about OpEx cuts offsetting LOE pressures and commitment to dividend. Albert Bourla discussed distinction between friendly and non-friendly countries in tariff considerations.

Q: Chris Schott asked about gross margins and conservatism in guidance.

A: Dave Denton stated the company is off to a solid start, maintained guidance, and focused on improving gross and operating margins.

Q: Geoff Meacham asked about strategy prioritization in BD and tariff negotiation incentives.

A: Andrew Baum spoke about TAM, LOE, value, and sustainable franchises in BD. Albert Bourla discussed incentives like reduced taxes for locally produced goods to invest in US manufacturing.

Q: Trung Huynh asked about cost realignment savings and BD in macro environment.

A: Dave Denton commented on cost savings timing, and Andrew Baum spoke about BD in volatile macro environment.

Q: Carrie Halford asked about US drug sales end-to-end in US and crude royalties.

A: Albert Bourla and Dave Denton discussed non-disclosure of production details and impact of IRA and FX on revenues.

Q: Akash Tewari asked about tariff bottom line impact.

A: Albert Bourla was cautious, emphasizing contingency plans but not specific single-digit impact statements.

Q: Terence Flynn asked about grand bargain on tariffs and pipeline data.

A: Albert Bourla discussed administration focus on 340B, pill penalty, etc., and Chris Boshoff commented on phase three data for Varetech two.

Q: Dave Risinger asked about Washington's approach to biotechnology and 232 investigation progress.

A: Albert Bourla commented on concerns about scientific approaches and 232 investigation progress, with Chris Boshoff discussing pipeline readouts.

Q: Mohit Bansal asked about API manufacturing focus in tariffs.

A: Albert Bourla discussed focus on entire value chain for national security, including APIs and product manufacturing.

Q: Courtney Breen asked about tariffs and pipeline R&D day.

A: Albert Bourla and Chris Boshoff discussed inventory mitigation for tariffs and pipeline readouts, with Chris Boshoff mentioning phase three programs and flash events for pipeline visibility.

Q: Asad Hadir asked about Vindipul competition, internal oral keto agonist timelines, and analyst model disconnects.

A: Aamir Malik and Alexandre de Germay discussed Vindipul performance, Chris Boshoff spoke about oral keto agonist phase two timeline, and Andrew Baum addressed analyst model disconnects on ADCs, CIDIF, CDK four, and ponsagramab.